MERCURY BIO - Trademark Details
Status: 630 - New Application - Record Initialized Not Assigned To Examiner
Serial Number
98602178
Word Mark
MERCURY BIO
Status
630 - New Application - Record Initialized Not Assigned To Examiner
Status Date
2024-06-14
Filing Date
2024-06-14
Mark Drawing
4 - Standard character mark
Attorney Name
Statements
Goods and Services
Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, yeast derived extracellular vesicle-based delivery systems for pharmaceuticals, therapeutics, and biologics; Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, development of humanized yeast extracellular vesicles delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics, namely genetically engineering yeast cells to produce extracellular vesicles for delivery of pharmaceuticals, therapeutics, and biologics; Bioinformatics, namely genetically engineering yeast cells to produce humanized extracellular vesicles delivery of for pharmaceuticals, therapeutics, and biologics; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, yeast-derived extracellular vesicle-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for vaccines; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for pharmaceutical compounds; Research and development of the production of extracellular vesicles for therapeutic uses, namely, yeast-derived extracellular vesicles for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications; and Design and development of loading systems to load nucleic acids, proteins, enzymes, and drug compounds into yeast-derived extracellular vesicles for therapeutic uses
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2024-06-14
Primary Code
042
First Use Anywhere Date
2023-01-17
First Use In Commerce Date
2023-01-17
Current Trademark Owners
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
David S. Kerr Berg Hill Greenleaf Ruscitti LLP
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2024-06-14 | NEW APPLICATION ENTERED |
2024-06-14 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |